Technical Analysis for ONCR - Oncorus, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 28.8 | 3.86% | 1.07 |
ONCR closed up 3.86 percent on Friday, January 15, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Up | Down |
Historical ONCR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 50 DMA | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 50 DMA | Bearish | 3.86% | |
180 Bearish Setup | Bearish Swing Setup | 3.86% | |
Multiple of Ten Bearish | Other | 3.86% | |
Wide Bands | Range Expansion | 3.86% | |
Down 3 Days in a Row | Weakness | 3.86% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakout | 1 day ago | |
Up 5% | 1 day ago | |
Up 3% | 1 day ago | |
Down 2 % | 1 day ago | |
Down 1% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Brain Cancer Oncolytics Biotech Herpes Simplex Herpes Simplex Virus Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Brain Cancer Oncolytics Biotech Herpes Simplex Herpes Simplex Virus Oncolytic Virus
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 37.8603 |
52 Week Low | 14.6 |
Average Volume | 113,335 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 28.12 |
20-Day Moving Average | 32.36 |
10-Day Moving Average | 32.02 |
Average True Range | 3.38 |
ADX | 30.22 |
+DI | 16.38 |
-DI | 21.86 |
Chandelier Exit (Long, 3 ATRs ) | 27.73 |
Chandelier Exit (Short, 3 ATRs ) | 36.13 |
Upper Bollinger Band | 37.23 |
Lower Bollinger Band | 27.49 |
Percent B (%b) | 0.13 |
BandWidth | 30.11 |
MACD Line | 0.49 |
MACD Signal Line | 1.48 |
MACD Histogram | -0.9922 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 31.79 | ||||
Resistance 3 (R3) | 31.57 | 30.36 | 31.29 | ||
Resistance 2 (R2) | 30.36 | 29.60 | 30.47 | 31.12 | |
Resistance 1 (R1) | 29.58 | 29.13 | 29.97 | 29.80 | 30.96 |
Pivot Point | 28.37 | 28.37 | 28.57 | 28.48 | 28.37 |
Support 1 (S1) | 27.59 | 27.61 | 27.98 | 27.81 | 26.64 |
Support 2 (S2) | 26.38 | 27.14 | 26.49 | 26.48 | |
Support 3 (S3) | 25.60 | 26.38 | 26.31 | ||
Support 4 (S4) | 25.82 |